Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vanda Pharmaceutical (VNDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,055,294
  • Shares Outstanding, K 52,450
  • Annual Sales, $ 165,080 K
  • Annual Income, $ -15,570 K
  • 36-Month Beta 0.70
  • Price/Sales 5.00
  • Price/Cash Flow N/A
  • Price/Book 3.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.06
  • Growth Rate Est. (year over year) +1,664,900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.05 +22.14%
on 02/11/19
31.30 -33.47%
on 01/18/19
-8.47 (-28.90%)
since 01/15/19
3-Month
17.05 +22.14%
on 02/11/19
33.44 -37.72%
on 12/03/18
-3.00 (-12.61%)
since 11/15/18
52-Week
13.88 +50.09%
on 05/01/18
33.44 -37.72%
on 12/03/18
+3.93 (+23.22%)
since 02/15/18

Most Recent Stories

More News
VANDA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals Inc. To Contact The Firm

NEW YORK, NY / ACCESSWIRE / February 14, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vanda Pharmaceuticals Inc. ("Vanda" or the "Company")(NASDAQ:...

VNDA : 20.92 (+3.98%)
ONGOING INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or "the Company") (NASDAQ: VNDA)...

VNDA : 20.92 (+3.98%)
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Vanda Pharmaceuticals Inc. Investors

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Vanda Pharmaceuticals Inc. investors ("Vanda" or the "Company") (NASDAQ: VNDA) concerning the Company and...

VNDA : 20.92 (+3.98%)
Vanda Pharmaceuticals (VNDA) Tops Q4 Earnings and Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of 100.00% and 3.33%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

VNDA : 20.92 (+3.98%)
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Vanda Pharmaceuticals Inc. Investors (VNDA)

Law Offices of Howard G. Smith announces an investigation on behalf of Vanda Pharmaceuticals Inc. investors ("Vanda" or the "Company") (NASDAQ: VNDA) concerning the Company and its officers'...

VNDA : 20.92 (+3.98%)
Vanda: 4Q Earnings Snapshot

WASHINGTON (AP) _ Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported fourth-quarter net income of $10.4 million, after reporting a loss in the same period a year earlier.

VNDA : 20.92 (+3.98%)
Vanda Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2018.

VNDA : 20.92 (+3.98%)
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or "the...

VNDA : 20.92 (+3.98%)
Vanda Pharmaceuticals Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 13, 2019 / Vanda Pharmaceuticals Inc. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 13, 2019 at...

VNDA : 20.92 (+3.98%)
VANDA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Vanda Pharmaceuticals Inc. ("Vanda" or the "Company")(NASDAQ:VNDA).

VNDA : 20.92 (+3.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

See More Share

Trade VNDA with:

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

2nd Resistance Point 21.55
1st Resistance Point 20.83
Last Price 20.92
1st Support Level 19.04
2nd Support Level 17.97

See More

52-Week High 33.44
Fibonacci 61.8% 25.97
Fibonacci 50% 23.66
Fibonacci 38.2% 21.35
Last Price 20.92
52-Week Low 13.88

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar